CD8A and neoplasm: Additional controls showed that the CD8+ or CD4+ Teff cell responses against multiple peptides derived from a known lung antigen, such as NY-ESO-156,57, increased upon chemotherapy, and even more upon nivolumab treatments in the peripheral blood of some patients tested, supporting the possibility that also conventional tumor antigens can be unveiled by chemotherapy (Supplementary Fig. 12).